debrisoquin has been researched along with Psoriasis in 2 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chapman, PH | 2 |
Rawlins, MD | 2 |
Shuster, S | 2 |
Idle, JR | 2 |
Ritchie, JC | 1 |
Smith, RL | 2 |
Mahgoub, A | 1 |
Mucklow, JC | 1 |
Rogers, S | 1 |
2 other studies available for debrisoquin and Psoriasis
Article | Year |
---|---|
Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.
Topics: Administration, Oral; Adult; Debrisoquin; Heme Oxygenase (Decyclizing); Humans; Hydroxylation; Isoqu | 1981 |
4-Hydroxylation of debrisoquine in psoriasis [proceedings].
Topics: Debrisoquin; Humans; Hydroxylation; Isoquinolines; Psoriasis | 1980 |